2009
DOI: 10.14219/jada.archive.2009.0072
|View full text |Cite
|
Sign up to set email alerts
|

Treating Oral Histoplasmosis in an Immunocompetent Patient

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
5
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 23 publications
(20 reference statements)
1
5
0
Order By: Relevance
“…There are no guidelines or recommendations specific to the treatment of primary cutaneous histoplasmosis owing to the rarity of this condition. However, the resolution of our patient's symptoms with oral itraconazole is consistent with the previously reported cases of primary mucocutaneous histoplasmosis in immunocompetent patients responding to this therapy [1][2][3][4][5][13][14][15]. Despite the known risk of hepatic toxicity with itraconazole and the history of liver cirrhosis in our patient, itraconazole therapy with appropriate laboratory monitoring, including itraconazole levels and liver function tests, was the most appropriate treatment regimen in our patient.…”
Section: Discussionsupporting
confidence: 89%
See 1 more Smart Citation
“…There are no guidelines or recommendations specific to the treatment of primary cutaneous histoplasmosis owing to the rarity of this condition. However, the resolution of our patient's symptoms with oral itraconazole is consistent with the previously reported cases of primary mucocutaneous histoplasmosis in immunocompetent patients responding to this therapy [1][2][3][4][5][13][14][15]. Despite the known risk of hepatic toxicity with itraconazole and the history of liver cirrhosis in our patient, itraconazole therapy with appropriate laboratory monitoring, including itraconazole levels and liver function tests, was the most appropriate treatment regimen in our patient.…”
Section: Discussionsupporting
confidence: 89%
“…In addition to histoplasmosis, other maladies including malignant neoplasms such as squamous cell carcinoma, persistent trauma, ulcerative lichen planus, and autoimmune blistering disorders are in the differential diagnosis [1,5]. When the diagnosis of primary mucocutaneous histoplasmosis is made, treatment with oral itraconazole is appropriate and has led to resolution of cases described in the literature and presented here [1][2][3][4][14][15].…”
Section: Discussionmentioning
confidence: 99%
“…In immunocompromised patients such as those with HIV presenting with limited or disseminated disease, intravenous liposomal amphotericin B is the treatment of choice as the regular (amphotericin B deoxycholate) form is less used due to adverse reactions [ 48 ]. However, in immunocompetent patients and those with localized disease, itraconazole is the preferred treatment modality as it is safe and has low toxicity compared to amphotericin [ 49 , 50 ]. The prognosis in immunocompetent patients having mild to moderate infections is usually good.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, immunocompetent individuals may have endogenous reactivation of the disease which may present at a later stage of life, as observed in tuberculosis [8]. Oral involvement in the form of chronic non-healing ulcer or mass lesion of the buccal mucosa, tongue, and palate are seen in 25%–40% of patients with PDH [9]. Oral manifestation of histoplasmosis, though usually associated with chronic disseminated form of the disease, constitutes a rare entity in immunocompetent individuals.…”
Section: Discussionmentioning
confidence: 99%